- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Gordon K Wilcock, University of Oxford
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
Novel drug candidate J147 is able to arrest and reverse memory deficits and improve several aspects of brain function in aged mice with advanced symptoms of Alzheimer's disease (AD).
Clark and Kodadek review the current progress to identify Alzheimer's disease (AD)-specific blood-based protein biomarkers, which would allow for an economical, rapid and non-invasive diagnostic test for the disease.
Lecanu and Papadopoulos discuss pharmacologically induced rat models of sporadic Alzheimer's disease (AD) and their potential benefits for drug development over transgenic alternatives.
Treatments that increase norepinephrine transmission and may have the potential to delay or reverse Alzheimer's disease-related pathology are discussed by Levey and colleagues, who review the evidence for noradrenergic-based therapies.
María Javier Ramírez reviews evidence supporting the cognitive effects of 5-HT6 receptor compounds, resulting in 5-HT6-targeted compounds being regarded as powerful therapeutic candidates in Alzheimer's disease (AD).
A new long-lasting analogue of glucose-dependent insulinotropic polypeptide (GIP) has neuroprotective properties including rescuing cognitive performance and reducing Abeta plaque load and neuroinflammation in an animal model of Alzheimer's disease.
A novel gamma-secretase modulator (GSM) and promising new therapy in Alzheimer’s disease (AD) is orally bioavailable, brain penetrant, and effective at lowering Abeta42 in a dose responsive manner in multiple rodent models.
- View more articles
News from Alzforum
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
Latest free review
The following review has recently become free to access:
Sally Hunter, Carol BrayneAlzheimer's Research & Therapy 2012, 4:10 (13 April 2012)
Cognitive enhancers for ageing and Alzheimer's disease
Published: 22 April 2013
Last updated: 14 May 2013
Published: 4 March 2013
Last updated: 9 May 2013